DCGO Nasdaq Services-Health Services Financials FY2020βFY2025
DocGo Inc. had $322M of revenue in fiscal 2025, down 47.7% on the year before. Over five years, revenue changed +27.9% a year on average.
Last close Β· Oct 23, 2026
$0.27
0.4%Hi! I read DocGo Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β47.7%
No. Sales fell 47.7% last year.
Does it make a profit?
β56.6%
No. It lost money last year.
Does profit turn into cash?
9.3%
Partly. 9.3% of sales ends up as free cash.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days DocGo Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 9, 2026
Monday Β· in 15 days
No past results dates on file yet.
KIRA Β· DocGo Inc. had $322M of revenue in fiscal 2025, down 47.7% on the year before. Over five years, revenue changed +27.9% a year on average. Its operating margin was β55.3%, down 59.9Β pts: of every 100 in sales, about β55 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
KIRA Β· DocGo Inc. lost $182M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $29.9M in fiscal 2025, 9.3% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
KIRA Β· DocGo Inc. returned $10.8M to shareholders in fiscal 2025, 36% of free cash flow. The diluted share count fell 9.5%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· DocGo Inc. has $34.1M more cash than debt.
Cash, debt and the ratios that show how comfortably DocGo Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $176M | $157M | $59.3M | $89.2M | $51.0M |
| Debt incl. finance leases | $10.7M | $9.3M | $11.5M | $14.7M | $17.0M |
| Net debt / EBITDA | β9.3x | β4.6x | β1.5x | β1.7x | β |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | 250.5x | 966.0x | β | β | β |
| Current ratio | 4.4x | 2.7x | 2.0x | 2.5x | 2.3x |
| Quick ratio | 4.4x | 2.7x | 2.0x | 2.5x | 2.3x |
| Total assets | $310M | $393M | $490M | $456M | $217M |
| Total liabilities | $82.5M | $114M | $185M | $140M | $91.2M |
| Shareholders' equity | $220M | $273M | $301M | $321M | $144M |
| Net debt (β = net cash) | β$165M | β$148M | β$47.8M | β$74.5M | β$34.1M |
KIRA Β· Its return on capital was β150.9%: every 100 invested in the business earned about β151 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
KIRA Β· DocGo Inc. passes 4 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 6 / 9 | 3 / 8 | 7 / 8 | 4 / 8 |
| Accruals ratio | β4.1% | 12.5% | 1.6% | 16.1% | β10.6% | β64.5% |
| Altman Z'' | 0.19 | 6.66 | 5.49 | 4.03 | 5.44 | β4.05 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $94.1M | $319M | $441M | $624M | $617M | $322M |
| Net interest income | β$0.2M | β$0.8M | $0.8M | $1.7M | β | β |
| Gross profit | β | β$133M | β$83.4M | β | β | β |
| Research and development | $1.2M | $3.3M | $5.4M | $10.9M | $11.6M | $13.6M |
| Operating income | β$14.8M | $15.4M | $21.8M | $15.1M | $28.7M | β$178M |
| Interest expense | $0.0M | $0.1M | $0.0M | β | β | β |
| Pretax income | β$14.6M | $19.8M | $22.8M | $16.3M | $27.7M | β$187M |
| Income tax | $0.2M | $0.6M | β$8.0M | $6.2M | $14.4M | $8.9M |
| Net income | β$14.8M | $23.7M | $34.6M | $6.9M | $20.0M | β$182M |
| Net income to common | β$14.4M | $23.7M | $34.6M | $6.9M | $20.0M | β$182M |
| Diluted EPS | β$0.25 | $0.25 | $0.34 | $0.06 | $0.18 | β$1.84 |
| Diluted shares | 0.06B | 0.09B | 0.10B | 0.11B | 0.11B | 0.10B |
| Cash flow | ||||||
| Cash from operations | β$10.7M | β$1.9M | $28.9M | β$64.5M | $70.1M | $34.5M |
| Capital expenditure | $4.4M | $4.8M | $3.2M | $7.3M | $3.6M | $4.5M |
| Free cash flow | β$15.0M | β$6.8M | $25.7M | β$71.8M | $66.5M | $29.9M |
| Depreciation and amortization | $5.5M | $2.3M | $10.6M | $16.4M | $15.9M | $15.7M |
| Stock-based compensation | β | $1.4M | $8.1M | $21.0M | $13.6M | $17.4M |
| Acquisitions | β | $1.3M | $33.0M | $20.2M | $0.0M | $16.4M |
| Share buybacks | β | $0.0M | $3.7M | $0.0M | $13.8M | $10.8M |
| Dividends and buybacks | β | $0.0M | $3.7M | $0.0M | $13.8M | $10.8M |
| Balance sheet | ||||||
| Cash and short-term investments | $32.4M | $176M | $157M | $59.3M | $89.2M | $51.0M |
| Total debt | $0.1M | $0.6M | $0.7M | $0.1M | $0.0M | $0.2M |
| Finance lease liabilities | $7.4M | $10.1M | $8.6M | $11.4M | $14.7M | $16.7M |
| Current assets | $58.4M | $256M | $271M | $339M | $304M | $152M |
| Current liabilities | $23.5M | $57.9M | $100M | $170M | $122M | $67.5M |
| Property and equipment, net | $9.1M | $12.7M | $21.3M | $16.8M | $14.9M | $14.6M |
| Goodwill | $6.6M | $8.7M | $38.9M | $47.5M | $47.4M | $0.0M |
| Intangible assets | $10.7M | $10.7M | $23.0M | $37.7M | $25.7M | $0.0M |
| Total assets | $100M | $310M | $393M | $490M | $456M | $217M |
| Total liabilities | $33.2M | $82.5M | $114M | $185M | $140M | $91.2M |
| Shareholders' equity | $55.0M | $220M | $273M | $301M | $321M | $144M |
| Margins | ||||||
| Gross margin | β | β41.7% | β18.9% | β | β | β |
| Operating margin | β15.7% | 4.8% | 5.0% | 2.4% | 4.7% | β55.3% |
| EBITDA margin | β9.8% | 5.5% | 7.4% | 5.0% | 7.2% | β50.4% |
| Net margin | β15.7% | 7.4% | 7.9% | 1.1% | 3.2% | β56.6% |
| FCF margin | β16.0% | β2.1% | 5.8% | β11.5% | 10.8% | 9.3% |
| Net interest share of revenue | β0.2% | β0.2% | 0.2% | 0.3% | β | β |
| Returns | ||||||
| Return on capital | β51.3% | 33.3% | 18.7% | 4.1% | 8.0% | β150.9% |
| Return on capital employed | β19.2% | 6.1% | 7.4% | 4.7% | 8.6% | β119.0% |
| Return on equity | β26.9% | 17.3% | 14.0% | 2.4% | 6.4% | β78.5% |
| Return on assets | β14.8% | 11.6% | 9.8% | 1.6% | 4.2% | β54.2% |
| Return on tangible equity | β38.1% | 11.9% | 16.4% | 3.2% | 8.1% | β126.7% |
| Growth | ||||||
| Revenue growth | β | 238.7% | 38.2% | 41.7% | β1.2% | β47.7% |
| Net income growth | β | β | 45.7% | β80.2% | 191.5% | β1,012.4% |
| EPS growth | β | β | 36.0% | β82.4% | 200.0% | β1,122.2% |
| FCF growth | β | β | β | β379.7% | β | β55.0% |
| Share count change | β | 62.5% | 8.6% | 2.6% | 3.6% | β9.5% |
| Financial health | ||||||
| Net debt / EBITDA | β | β9.3x | β4.6x | β1.5x | β1.7x | β |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | β934.0x | 250.5x | 966.0x | β | β | β |
| Current ratio | 2.5x | 4.4x | 2.7x | 2.0x | 2.5x | 2.3x |
| Quick ratio | 2.5x | 4.4x | 2.7x | 2.0x | 2.5x | 2.3x |
| Capital allocation | ||||||
| Capex / revenue | 4.6% | 1.5% | 0.7% | 1.2% | 0.6% | 1.4% |
| Stock comp / revenue | β | 0.4% | 1.8% | 3.4% | 2.2% | 5.4% |
| Payouts / FCF | β | β | 14.5% | β | 20.7% | 36.2% |
| Quality scores | ||||||
| Piotroski F-score | β | 4.0 | 6.0 | 3.0 | 7.0 | 4.0 |
| Altman Z'' | 0.2 | 6.7 | 5.5 | 4.0 | 5.4 | β4.0 |
| Accruals ratio | β4.1% | 12.5% | 1.6% | 16.1% | β10.6% | β64.5% |
Source: SEC EDGAR XBRL filings (CIK 0001822359). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
